|Mark Michalski, MD, Executive Director, MGH and BWH Center for Clinical Data Science|
Machine learning is an emerging technology with promise to impact a wide variety of areas throughout the healthcare enterprise. In this discussion, we’ll review advances in machine learning and their potential impact on several areas of healthcare, with special focus in diagnostic areas. In addition, we’ll discuss some of the challenges and approaches that have been taken to translate this technology at the Partners organization.
Mark H. Michalski, MD is currently the Executive Director of the MGH & BWH Center for Clinical Data Science (CCDS). Mark has held this role since the inception of the CCDS in 2Q 2017, which is focused translating machine learning systems for improvements in diagnostics, population health, clinical informatics, and hospital operations. In the first year, Mark led two strategic partnerships, established a technical organization of over 20 FTEs, and oversaw the development of a GPU cluster with over a petaflop of compute. Previous to this role, Dr. Michalski held leadership and operational roles at early-stage companies in the medical software and device domain, including Butterfly Network (2013-2016) – a medical device company focused on ultrasound and ASIC development – and Hyperfine Research (2014-2016) – a stealth medtech company. Dr. Michalski held additional strategic roles in healthcare-focused efforts at Google (2008) and Genentech (2009-2010). Dr. Michalski completed his radiology residency training as a Holman Fellow at Yale-New Haven Hospital (2011-2015). He graduated with a degree in Cybernetics from the University of California at Los Angeles with multiple honors (2004) and received his medical degree from Stanford University (2010).